NCT07754409 Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
| NCT ID | NCT07754409 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Göteborg University |
| Condition | Non-Small Cell Carcinoma of Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2026-09-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Current oncological treatment for patients with locally advanced lung cancer comprise adjuvant immunotherapy (immune checkpoint inhibitors-ICI) as an additional one-year treatment after chemoradiotherapy which increases overall survival and progression-free survival. Patients with lung cancer have a high burden of distressful symptoms at diagnosis and during chemoradiotherapy. Side-effects from immunotherapy differs, they are unspecific and may develop at any point during treatment. However, it is not investigated thoroughly during adjuvant treatment in locally advanced lung cancer. As new oncological treatments are being introduced, focus must be placed on patients quality of life and how patients endure treatment to be able to know how to best support patients during this treatment. The knowledge gained from this project include how adjuvant immunotherapy treatment impacts health. This knowledge is sparse due to the novelty of the treatment.
Eligibility Criteria
Inclusion Criteria: * Patients with locally advanced non-small lung cancer * cared for at either one of two specialized oncology centres * ≥ 18 years of age * planned for concurrent chemoradiotherapy including ICI for 12 months * performance status 0-2. Exclusion Criteria: * diseases or comorbidities that may have significant impact on the outcome variables * limited understanding of the Swedish language preventing the possibility to give oral and written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07754409 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-Small Cell Carcinoma of Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07754409 currently recruiting?
Yes, NCT07754409 is actively recruiting participants. Contact the research team at sofie.jakobsson@fhs.gu.se for enrollment information.
Where is the NCT07754409 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT07754409 clinical trial?
NCT07754409 is sponsored by Göteborg University. The trial plans to enroll 75 participants.